ClinicalTrials.gg
Status unknownNCT05608980Updated Nov 8, 2022

0.01% Hypochlorous Acid in the Treatment of Blepharitis

An interventional study of 0.01% hypochlorous acid and Placebo in Blepharitis, sponsored by Eye & ENT Hospital of Fudan University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2022, registered Oct 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

02

Conditions studied

  • Blepharitis

Keywords

  • Blepharitis
  • Hypochlorous Acid
  • Eyelid cleanser
  • Eyelid hygiene
  • Meibomian gland dysfunction
03

In context

Blepharitis

73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 65 interventional studies indexed under Blepharitis.

Browse Blepharitis studies →

Lead sponsor

Eye & ENT Hospital of Fudan University is the lead sponsor of 126 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 or older.
  2. Anterior or mixed (anterior + posterior) blepharitis.
  3. Similar clinical condition of both eyes.
  4. A negative urine pregnancy test result for women of
  5. Normal lid position and closure
  6. Ability to understand and provide to participate in this study
  7. Willingness to follow study instructions and likely to complete all required visits.

Exclusion criteria

Exclusion Criteria:

  1. Any ocular surface disease other than blepharitis.
  2. Known allergy to hypochlorous acid or boric acid.
  3. Eye surgery in the last 6 months.
  4. History of Stevens-Johnson syndrome or ocular pemphigoid
  5. Ocular trauma in the last 6 months.
  6. Use of contact lenses in the last 6 months.
  7. Pregnancy or lactation.
  8. Daily use of makeup on lashes.
  9. Any ocular or systemic medication that might affect the ocular microbiota (antibiotics, , ).
  10. Pregnant or lactating women
  11. Signs of current infection, including fever and current treatment with antibiotics
  12. Liver, renal, or hematologic disease
  13. The use of any other drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Treatment arm

    0.01%hypochlorous acid group

    Drug: 0.01% hypochlorous acid

  • Placebo comparator
    Placebo

    eyelid wipes

    Drug: Placebo

Interventions

  • once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks

    Also known as: 0.01%HOCI

  • DrugPlacebo

    once daily eyelid wipes for 2 weeks

06

What researchers measure

Primary outcomes

  1. OSDI

    0-100 score based on the ocular surface disease index (OSDI) questionnaire

    Time frame: Change from baseline OSDI at 2 weeks

  2. meibum quality

    Meibum quality were measured by using firm digital pressure applied over 5 lower lid glands. Meibum quality was graded as: grade 0, clear; grade 1, cloudy; grade 2, cloudy with granular debris; and grade 3, thick like toothpaste.

    Time frame: Change from baseline meibum quality score at 2 weeks

  3. Corneal fluorescein staining

    scored by Oxford staining score

    Time frame: Change from baseline corneal fluorescein staining at 2 weeks

  4. FBUT

    fluorescent tear break up time fluorescein tear film break-up time

    Time frame: Change from baseline FTBUT at 2 weeks

07

Study locations

1 of 1 sites recruiting
  • Eye & ENT Hospital of Fudan University
    Shanghai, Shanghai, China
    Recruiting
    • Jiaxu Hong, phD · Contactjiaxu_hong@163.com · 13917440201
    • Hong Zhang, MsC · Principal investigator
    • Yuqing Wu, MsC · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2022, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 8, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Dec 1, 2022
CompletionEst.
May 1, 2023
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05608980
Collaborators
ShuGuang Hospital
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Jul 1, 2022
Primary completion
Dec 1, 2022 (estimated)
Completion
May 1, 2023 (estimated)
Last update
Nov 8, 2022

Study contacts

Jiaxu Hong
Contact
jiaxu_hong@163.com
13917440201
Jiaxu Hong
principal investigator · Eye & ENT Hospital of Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hypochlorous Acid

Start the discussion